San Diego, CA, United States of America

Alok Singh

This inventor holds 1 USPTO granted patent. Top assignee: Sorrento Therapeutics, Inc.. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Alok Singh. Retrieved from https://idiyas.com/inventor/alok-singh-drylk9t1

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Alok Singh: Innovator in Engineered Antibodies

Introduction

Alok Singh is a prominent inventor based in San Diego, California. He has made significant contributions to the field of biotechnology, particularly in the development of engineered antibodies. His innovative work has the potential to impact therapeutic approaches in various medical conditions.

Latest Patents

Alok Singh holds a patent for "Engineered Antibodies That Bind LAG3." This patent represents a crucial advancement in the understanding and treatment of immune-related diseases. With 1 patent to his name, Singh's work exemplifies the intersection of science and innovation.

Career Highlights

Alok Singh is currently employed at Sorrento Therapeutics, Inc., where he continues to push the boundaries of antibody engineering. His role at the company allows him to collaborate with other experts in the field, further enhancing his contributions to biotechnology.

Collaborations

Due to space constraints, the details of Alok Singh's collaborations will not be included.

Conclusion

Alok Singh's work in engineered antibodies showcases his dedication to advancing medical science. His innovative spirit and commitment to research make him a valuable asset in the field of biotechnology.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…